The Cochlear (ASX:COH) share price tumbles 7% despite dividend boost

The implantable hearing device developer released it FY21 results this morning.

| More on:
Boxer falls down in the ring, indicating a share price performance low.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Ltd (ASX: COH) share price is tumbling in late morning trade, down 7.4% to $237.08 per share.

This comes despite the ASX healthcare company meeting guidance in its full year results for the 2021 financial year, released earlier today. And despite a boost to its dividend payout.

What dividend did Cochlear announce?

The Cochlear share price is falling even though the company boosted its full-year dividend by 59%, to $2.55.

Management was able to return some cash to investors' pockets after Cochlear saw sales revenue grow 10% in FY21, reaching $1.49 billion. Underlying net profit of $236.7 million was also up 54% year-on-year. And profits beat guidance, which management had forecast would come in the range of $225–245 million.

That, however, appears not to have satisfied many investors, with Cochlear dropping heavily even as the S&P/ASX 200 Index (ASX: XJO) edges up 0.3%.

So, why is the Cochlear share price tumbling?

My Foolish colleague James Mickleboro may have nailed the answer to that question before markets opened today, writing:

While Cochlear's profit was within its guidance range, it appears to have fallen short of the market's expectations. According to CommSec, the analyst consensus was a net profit after tax of $245.5 million. This could potentially weigh on the Cochlear share price today.

It's not uncommon for investors to punish stocks that fall short of consensus expectations.

Cochlear share price snapshot

Even with today's large drop, the Cochlear share price remains a standout performer in 2021, up 28% year-to-date. That's more than double the gains posted by the ASX 200 this calendar year.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Healthcare Shares

Why are Mesoblast shares jumping 10% to a 52-week high?

This biotech is hitting new highs on Friday. Let's find out why.

Read more »

a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
Healthcare Shares

Ansell shares tumble to a 3-month low. Is this a buying opportunity?

Ansell shares have slid to a 3-month low. Could oversold signals point to a buying opportunity for long-term investors?

Read more »

Female scientist working in a laboratory.
Healthcare Shares

These three biotechs show how the sector can produce huge outsized gains, but are they still good value?

These drug developers' shares are trading near 12-month highs.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence.
Healthcare Shares

This biotech is approaching 20-bagger status within a year and the good news continues to come

This company has just won approval to go ahead with a key clinical trial.

Read more »

An investor sits at a table in front of her laptop with a party hat on her head and a cake next to her symbolising new year's eve but the 4DS Memory share price is plunging so she looks very disappointed and depressed
Healthcare Shares

$5 billion ASX 200 healthcare stock tumbling on CEO exit

Investors are bidding down the ASX 200 healthcare giant on Thursday. Let’s see why.

Read more »

woman testing substance in laboratory dish, csl share price
Share Market News

After a 73% surge this ASX healthcare share looks far from done

Brokers are upbeat, and some see possible gains of 90% in 2026.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which biotech's shares are surging higher on US patent news?

Investors like what they see from this drug company.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This biotech company's shares are on a tear – again – after another contract win

A new contract with a prestigious US institution spells good news for shareholders.

Read more »